9:36 AM
Dec 18, 2014
 |  BC Innovations  |  Distillery Techniques

Techniques: Extending therapeutic protein half-lives via fusion to affibodies with pH-dependent, binding to neonatal Fc receptor

Drug platforms

TECHNOLOGY: Drug platforms

Fusing therapeutic proteins to affibodies with pH-dependent binding to neonatal Fc receptor could improve the proteins' half-lives. Binding to Fc receptors improves the half-life of biopharmaceuticals. Phage...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >